Literature DB >> 16308219

Drug-resistant tuberculosis in Yangon, Myanmar.

Sabai Phyu1, Thandar Lwin, Ti Ti, Win Maung, Win W Mar, San S Shein, Harleen M S Grewal.   

Abstract

The extent of drug resistant tuberculosis (TB) in the capital city of Myanmar, Yangon has not yet been reported. This study aimed to determine the proportion and pattern of drug resistance to first-line anti-TB drugs, among Mycobacterium tuberculosis complex isolates from sputum smear positive TB patients who attended National TB Programme Yangon centres in April-August and October-December 2002. Drug susceptibility was determined by the Mycobacteria Growth Indicator Tube manual system (Becton Dickinson, MD, USA). Of the 567 patients, sputum specimens from 447 (79%) had a positive culture. Of these, 357 isolates (80%) had a susceptibility test result. Isolates from 76 of 259 (29.3%) new patients and from 45 of 98 (45.9%) previously treated patients were resistant to at least 1 of the anti-TB drugs. Resistance to isoniazid (INH) (22.0% vs 40.8%: new vs previously treated patients) and to > or =2 drugs (17.8% vs 29.6%: new vs previously treated patients) was common. Multidrug- resistant TB (MDR-TB) among new and previously treated patients was 4.2% and 18.4%, respectively. INH-resistant (adjusted OR: 2.0, 95% CI 1.1-3.6) and MDR-TB (adjusted OR: 3.4, 95% CI 1.4-8.3) cases were more likely to have taken anti-TB drugs > or =1 month previously. Collectively, prevalence of MDR-TB and TB resistance to > or =2 drugs are not rare in Yangon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16308219     DOI: 10.1080/00365540500265065

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Predominance of Mycobacterium tuberculosis EAI and Beijing lineages in Yangon, Myanmar.

Authors:  Sabai Phyu; Ruth Stavrum; Thandar Lwin; Øyvind S Svendsen; Ti Ti; Harleen M S Grewal
Journal:  J Clin Microbiol       Date:  2008-11-26       Impact factor: 5.948

2.  IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence.

Authors:  J Ousley; K P Soe; N T T Kyaw; R Anicete; P E Mon; H Lwin; T Win; S Cristofani; A Telnov; M Fernandez; I Ciglenecki
Journal:  Public Health Action       Date:  2018-03-21

Review 3.  Responding to AIDS, tuberculosis, malaria, and emerging infectious diseases in Burma: dilemmas of policy and practice.

Authors:  Chris Beyrer; Voravit Suwanvanichkij; Luke C Mullany; Adam K Richards; Nicole Franck; Aaron Samuels; Thomas J Lee
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

4.  Genomic diversity among Beijing and non-Beijing Mycobacterium tuberculosis isolates from Myanmar.

Authors:  Ruth Stavrum; Håvard Valvatne; Trond H Bø; Inge Jonassen; Jason Hinds; Philip D Butcher; Harleen M S Grewal
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.